摘要
目的探究泽泻醇B(alisol B)抑制非小细胞肺癌(non-small cell lung cancer,NSCLC)的潜在基因与机制。方法通过CCK-8和Transwell检测泽泻醇B对NSCLC细胞的增殖及迁移作用。通过TCGA和化合物基因预测数据库收集NSCLC和泽泻醇B的基因,并获得二者交集基因。应用String数据库构建蛋白-蛋白分子相互作用(protein protein interaction,PPI)网络,筛出前20的节点,运用R语言筛出与NSCLC预后相关的蛋白,并获得二者交集;通过KEGG和GO富集分析及相关基因与免疫细胞关系分析探究泽泻醇B作用于NSCLC的潜在机制,并通过细胞水平实验验证。结果泽泻醇B抑制NSCLC细胞的细胞活力和迁移能力。通过网络药理学分析确定5个重要基因:CCNE1,CDK1,COL1A1,COL1A2,COL3A1;细胞实验结果显示泽泻醇B下调NSCLC细胞中Cyclin E1、CDK1和COL1A2的表达。此外,泽泻醇B可抑制巨噬细胞中COL1A2和M2型巨噬细胞标志物CD206的表达。结论泽泻醇B可能通过下调CDK1和Cyclin E1抑制肿瘤细胞增殖,并可能通过抑制COL1A2影响巨噬细胞功能,从而调控肿瘤免疫微环境,对NSCLC产生抑制作用。
Aim To explore the potential genes and mechanism of alisol B in the treatment of non-small cell lung cancer(NSCLC).Methods The proliferation and migration of NSCLC cells were detected by CCK-8 and Transwell.Genes of NSCLC and alisol B were collected through TCGA and compound gene prediction database,and their intersection genes were obtained.The network of protein-protein interaction(PPI)was constructed by using String database,and the top 20 key nodes were screened out,and the prognosis-related proteins related to the prognosis of NSCLC were screened out by using R language,and the intersection of them was obtained.The potential mechanism of alisol B on NSCLC was explored by KEGG and GO enrichment analysis and the relationship between related genes and immune cells,which was verified by cell-level experiments.Results Alisol B inhibited the cell activity and migration ability of NSCLC cells.Five important genes were identified by network pharmacological analysis:CCNE1,CDK1,COL1A1,COL1A2 and COL3A1.The results of cell experiment showed that alisol B down-regulated the expression of Cyclin E1,CDK1 and COL1A2 in NSCLC cells.In addition,alisol B could inhibit the expression of COL1A2 and M2 macrophage marker CD206 in macrophages.Conclusions Alisol B may inhibit the proliferation of tumor cells by down-regulating CDK1 and Cyclin E1,and may affect the function of macrophages by inhibiting COL1A2,thus regulating the tumor immune microenvironment and inhibiting NSCLC.
作者
向柳燕
王文萱
顾斯萌
张晓倩
李陆垚
李玉倩
王媛茹
雷琪琪
杨雪
曹亚军
李学军
XIANG Liu-yan;WANG Wen-xuan;GU Si-meng;ZHANG Xiao-qian;LI Lu-yao;LI Yu-qian;WANG Yuan-ru;LEI Qi-qi;YANG Xue;CAO Ya-jun;LI Xue-jun(Dept of Pharmacology and Key Laboratory of Xinjiang Phytomedicine Resource and Utilization,Ministry of Education,Shihezi University,Shihezi Xinjiang 832002,China;Dept of Pharmacology,School of Basic Medical Sciences,Peking University,Beijing 100191,China;Dept of Pharmacology,School of Pharmacy,Xinjiang Medical University,Urumuqi 830017,China)
出处
《中国药理学通报》
CAS
CSCD
北大核心
2024年第12期2375-2384,共10页
Chinese Pharmacological Bulletin
基金
国家自然科学基金资助项目(No 82073878,81874318)。